The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT ID: NCT00006187
Last Updated: 2009-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
INTERVENTIONAL
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients on stable doses of marketed cholinesterase inhibitors approved for the treatment of AD (except for tacrine) for at least 3 months are eligible for study entry. Use of NSAIDs (except aspirin 81 mg per day) is not allowed during the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Investigational drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female patients must be postmenopausal or surgically sterilized
* Clinical diagnosis of AD
* Patient must be in good health except for AD diagnosis
* Patient must have informant/caregiver who can monitor and assist patient during the study
Exclusion Criteria
* Women will be ineligible if not postmenopausal or surgically sterilized
* Site physician or Sponsor may exclude patients with serious medical problems such as cancer, cardiovascular disease, major neurological or psychiatric illness, thyroid disease, or major head trauma
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Klaus Beck, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pivotal Research Centers
Peoria, Arizona, United States
California Clinical Trials
Beverly Hills, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
Pharmacology Research Institute
Newport Beach, California, United States
Daniel Grosz MD
Northridge, California, United States
Pharmacology Research Institute
Riverside, California, United States
Pacific Research Network
San Diego, California, United States
San Francisco Headache Clinic
San Francisco, California, United States
Yale University, Alzheimer's Disease ResearchUnit
New Haven, Connecticut, United States
New England Center for Headache
Stamford, Connecticut, United States
Baumel-Eisner Neuromedical Institute
Boca Raton, Florida, United States
Baumel-Eisner Neuromedical Institute
Fort Lauderdale, Florida, United States
ICSL Clinical Studies
Fort Myers, Florida, United States
ICSL Clinical Studies
Melbourne, Florida, United States
ICSL Clinical Studies
Sarasota, Florida, United States
ICSL Clinical Studies
St. Petersburg, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Premiere Research Institute
West Palm Beach, Florida, United States
Palm Beach Neurological Center
West Palm Beach, Florida, United States
Chicago Center for Clinical Research
Chicago, Illinois, United States
ICSL Clinical Studies
South Yarmouth, Massachusetts, United States
Las Vegas Center for Clinical Research
Las Vegas, Nevada, United States
Nathan Klein Institute
Orangeburg, New York, United States
University of Rochester
Rochester, New York, United States
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
Pahl Brain Associates, P.C.
Oklahoma City, Oklahoma, United States
Clinical Pharmaceutical Trials
Tulsa, Oklahoma, United States
Pacific NW Clinical Research Center
Portland, Oregon, United States
Institute for Advanced Clinical Research
Elkins Park, Pennsylvania, United States
ICSL Clinical Studies
Philadelphia, Pennsylvania, United States
ICSL Clinical Studies
East Providence, Rhode Island, United States
Pharmacology Research Clinic
Salt Lake City, Utah, United States
Seattle Clinical Research Center
Seattle, Washington, United States
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IA0025
Identifier Type: -
Identifier Source: org_study_id